You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

CHLORHEXIDINE GLUCONATE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for chlorhexidine gluconate and what is the scope of freedom to operate?

Chlorhexidine gluconate is the generic ingredient in twenty-eight branded drugs marketed by Xttrium, Sage Prods, Medline Industries, Bajaj, Chartwell Rx, Lyne, Pharm Assoc, Sciegen Pharms Inc, Sunstar Americas, 3M, Colgate Palmolive Co, Colgate-palmolive Co, Soapco, Ecolab, Molnlycke Hlth, J And J, Matrix Medcl, Griffen, Becton Dickinson, Kendall Il, Carefusion 2200, Dexcel Pharma, 3m Health Care, Becton Dickinson Co, and Prof Dspls, and is included in thirty-six NDAs. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Chlorhexidine gluconate has three patent family members in one country.

There are twenty-seven drug master file entries for chlorhexidine gluconate. Fifty-seven suppliers are listed for this compound.

Summary for CHLORHEXIDINE GLUCONATE
Drug Prices for CHLORHEXIDINE GLUCONATE

See drug prices for CHLORHEXIDINE GLUCONATE

Drug Sales Revenue Trends for CHLORHEXIDINE GLUCONATE

See drug sales revenues for CHLORHEXIDINE GLUCONATE

Recent Clinical Trials for CHLORHEXIDINE GLUCONATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Ontario Clinical Oncology Group (OCOG)Phase 3
McMaster UniversityPhase 3
Hamilton Health Sciences CorporationPhase 3

See all CHLORHEXIDINE GLUCONATE clinical trials

Pharmacology for CHLORHEXIDINE GLUCONATE
Physiological EffectDecreased Cell Wall Integrity
Medical Subject Heading (MeSH) Categories for CHLORHEXIDINE GLUCONATE

US Patents and Regulatory Information for CHLORHEXIDINE GLUCONATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Colgate Palmolive Co PERIOGARD chlorhexidine gluconate SOLUTION;DENTAL 073695-001 Jan 14, 1994 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
3m PERIDEX chlorhexidine gluconate SOLUTION;DENTAL 019028-001 Aug 13, 1986 AT RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Sage Prods CHLORHEXIDINE GLUCONATE chlorhexidine gluconate CLOTH;TOPICAL 021669-001 Apr 25, 2005 OTC Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CHLORHEXIDINE GLUCONATE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Molnlycke Hlth HIBICLENS chlorhexidine gluconate SOLUTION;TOPICAL 017768-001 Approved Prior to Jan 1, 1982 ⤷  Subscribe ⤷  Subscribe
Dexcel Pharma PERIOCHIP chlorhexidine gluconate TABLET;DENTAL 020774-001 May 15, 1998 ⤷  Subscribe ⤷  Subscribe
Molnlycke Hlth HIBICLENS chlorhexidine gluconate SOLUTION;TOPICAL 017768-001 Approved Prior to Jan 1, 1982 ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for CHLORHEXIDINE GLUCONATE

Country Patent Number Title Estimated Expiration
Canada 2551688 DEBARBOUILLETTE NON TISSEE AMELIOREE (IMPROVED NON-WOVEN WASH CLOTH) ⤷  Subscribe
Canada 2467150 DISPOSITIF D'ADMINISTRATION DE DESINFECTANT ET METHODE DE DESINFECTION SANS ALCOOL (DISINFECTANT DELIVERY SYSTEM AND METHOD OF PROVIDING ALCOHOL-FREE DISINFECTION) ⤷  Subscribe
Canada 2467155 DISPOSITIF D'ADMINISTRATION DE DESINFECTANT ET METHODE DE DESINFECTION SANS ALCOOL (DISINFECTANT DELIVERY SYSTEM AND METHOD OF PROVIDING ALCOHOL-FREE DISINFECTION) ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

CHLORHEXIDINE GLUCONATE Market Analysis and Financial Projection Experimental

Chlorhexidine Gluconate Market Dynamics and Financial Trajectory

Market Overview

Chlorhexidine gluconate (CHG) is a widely used antiseptic agent known for its broad-spectrum antibacterial activity. It is available in various forms, including solutions, wipes, and dressings, and is integral in healthcare settings for preventing infections.

Market Size and Growth

The global chlorhexidine gluconate solution market is projected to experience steady growth over the coming years. As of 2022, the market size was estimated at USD 181.3 million and is expected to grow at a Compound Annual Growth Rate (CAGR) of 1.90% during the forecast period[4].

Forecast and Projections

By 2026, the chlorhexidine gluconate solution market is forecast to reach $196.1 million, growing at a CAGR of 3.2% from 2021 to 2026[1].

In the context of CHG wipes, the market is even more robust, with a projected size of $49.92 billion in 2024, growing from $47.4 billion in 2023 at a CAGR of 5.3%. This segment is expected to reach $61.46 billion by 2028[3].

Market Drivers

Increasing Surgical Procedures

The rise in the number of surgical procedures in hospitals is a significant driver for the chlorhexidine gluconate solution market. CHG is crucial for preoperative skin preparation and surgical hand rubs, reducing the risk of Surgical Site Infections (SSIs)[4].

Growing Geriatric Population

The increasing geriatric population, particularly in regions like North America and Asia-Pacific, is driving the demand for CHG solutions. This demographic shift leads to higher healthcare spending and an increased need for antiseptic agents[4].

Pandemic-Driven Hygiene Measures

The COVID-19 pandemic has heightened the importance of hygiene measures, including the use of hand sanitizers and disinfectants. This has boosted the demand for chlorhexidine gluconate solutions and wipes[3].

Regulatory Endorsement

Regulatory endorsements and guidelines emphasizing infection control have also contributed to the growth of the CHG market. Governments and health organizations have recommended the use of CHG for various medical applications, further driving its adoption[3].

Market Restraints

Volatility in Raw Material Prices

Fluctuations in the prices of raw materials required for the production of chlorhexidine gluconate solutions can act as a restraint. This volatility can lead to the emergence of substitutes and affect the overall market growth[4].

Stringent Regulatory Frameworks

Strict government regulations regarding the use of chemicals can also hinder the growth of the CHG market. Compliance with these regulations can increase costs and complexity for manufacturers[1].

Potential Health Risks

Research has indicated that high concentrations of chlorhexidine can be harmful, affecting various cells in the human body, such as gingival fibroblasts and osteoblastic cells. This could lead to cautious use and potential regulatory scrutiny[5].

Market Segmentation

By Type

The chlorhexidine gluconate solution market is segmented by type, with 2% CHG solutions holding the largest share. These solutions are used with and without isopropyl alcohol for various applications, including skin preparation for surgery, hand rubs, and wound cleaning[1].

By Application

The market is segmented by application into preoperative skin preparation, surgical hand rub, skin wound and general skin cleanser, and healthcare personal hand hygiene. The surgical hand rub segment accounted for the largest revenue share in 2022[4].

By Distribution Channel

CHG wipes are distributed through various channels, including pharmacies, supermarkets, specialty stores, and direct sales. This diverse distribution network ensures wide availability and accessibility[3].

By End User

The end users of CHG solutions and wipes include hospitals, clinics, ambulatory surgical centers, and other healthcare facilities. North America, with its advanced healthcare infrastructure, dominates the market, followed by Asia-Pacific and Europe[4].

Geographic Analysis

North America

North America leads the chlorhexidine gluconate solution market due to its well-developed healthcare sector and higher spending on healthcare. The region's aging population and the presence of advanced medical facilities are key factors driving this market[1][4].

Asia-Pacific

The Asia-Pacific region is expected to register the fastest revenue growth rate over the forecast period. This growth is attributed to the increasing geriatric population, rising healthcare spending, and expanding healthcare facilities in countries like China and India[4].

Europe

Europe is expected to experience steady growth, driven by an aging population and an increase in surgical procedures such as angioplasty. The European Commission's data indicates a significant rise in healthcare spending and surgical procedures in the region[4].

Cost-Benefit Analysis

The use of chlorhexidine gluconate dressings has been shown to have significant cost-benefit advantages. A study estimated that the potential annual U.S. net benefits from chlorhexidine dressing use could range from $275 million to $1.97 billion, along with a reduction in local infections, catheter-related bloodstream infections (CRBSIs), and mortality[2].

Competitive Landscape

The global chlorhexidine gluconate solution market is fragmented, with several key players dominating the market. These companies are engaging in strategies such as mergers and acquisitions, strategic agreements, and the development of new products to maintain their market share[4].

Key Takeaways

  • The chlorhexidine gluconate solution market is expected to grow steadily, driven by increasing surgical procedures and a growing geriatric population.
  • The market is segmented by type, application, distribution channel, and end user, with North America leading the global market.
  • Regulatory endorsements and pandemic-driven hygiene measures are significant drivers.
  • Volatility in raw material prices and potential health risks are key restraints.
  • The use of CHG dressings and solutions offers substantial cost-benefit advantages.

FAQs

What are the primary applications of chlorhexidine gluconate solutions?

Chlorhexidine gluconate solutions are primarily used for preoperative skin preparation, surgical hand rubs, skin wound and general skin cleansing, and healthcare personal hand hygiene[4].

How does the COVID-19 pandemic impact the chlorhexidine gluconate market?

The COVID-19 pandemic has increased the demand for chlorhexidine gluconate solutions and wipes due to heightened hygiene measures and the need for effective antiseptic agents[3].

What are the potential health risks associated with chlorhexidine gluconate?

High concentrations of chlorhexidine gluconate can be harmful, affecting cells such as gingival fibroblasts, gingival epithelial cells, and osteoblastic cells. However, when used correctly, it remains a valuable tool in infection control[5].

Which region dominates the chlorhexidine gluconate solution market?

North America dominates the chlorhexidine gluconate solution market due to its advanced healthcare infrastructure and higher healthcare spending[1][4].

What is the projected market size of the chlorhexidine gluconate solution market by 2026?

The chlorhexidine gluconate solution market is forecast to reach $196.1 million by 2026, growing at a CAGR of 3.2% from 2021 to 2026[1].

How does the cost-benefit analysis of chlorhexidine gluconate dressings look?

The use of chlorhexidine gluconate dressings can result in significant cost savings, ranging from $275 million to $1.97 billion annually in the U.S., along with reduced infections and mortality[2].

Sources

  1. IndustryARC: Chlorhexidine Gluconate Solution Market Overview - IndustryARC
  2. PubMed: Cost-benefit analysis of chlorhexidine gluconate dressing...
  3. The Business Research Company: Global Chlorhexidine Gluconate CHG Wipes Market Report 2024
  4. Emergen Research: Chlorhexidine Gluconate Solution Market Size - Emergen Research
  5. Today's RDH: Chlorhexidine: An Update - Today's RDH

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.